Acrivon Therapeutics, Inc.
ACRV
$8.46
-$0.01-0.12%
| Weiss Ratings | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -18.18% | |||
| 30-Day Total Return | 66.86% | |||
| 60-Day Total Return | 131.78% | |||
| 90-Day Total Return | 84.31% | |||
| Year to Date Total Return | 68.86% | |||
| 1-Year Total Return | -32.43% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -40.77% | |||
| 52-Week Low % Change | 165.52% | |||
| Price | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.30 | |||
| 52-Week Low Price | $3.19 | |||
| 52-Week Low Price (Date) | Feb 13, 2024 | |||
| 52-Week High Price (Date) | May 16, 2023 | |||
| Valuation | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 289.91M | |||
| Enterprise Value | 167.09M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.73 | |||
| Earnings Per Share Growth | -79.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.75 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $8.46 | |||
| Enterprise Value/EBITDA (TTM) | -2.08 | |||
| Enterprise Value/EBIT | -2.07 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 22.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 207 8979 | |||
| Address | 480 Arsenal Way Watertown, MA 02472 | |||
| Website | www.acrivon.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26.25% | |||
| Return on Equity | -- | |||
| Income Statement | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -66.57M | |||
| EBIT (TTM) | -67.10M | |||
| Net Income (TTM) | -60.39M | |||
| Net Income Avl. to Common (TTM) | -60.39M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -115.61% | |||
| EPS Diluted (TTM) | -2.73 | |||
| EPS Diluted Growth (Q YOY) | -7.08% | |||
| Balance Sheet | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 127.46M | |||
| Cash Per Share (Q) | $5.71 | |||
| Total Current Assets (Q) | 129.69M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 121.20M | |||
| Current Ratio (Q) | 9.749 | |||
| Book Value Per Share (Q) | $5.38 | |||
| Total Assets (Q) | 138.27M | |||
| Total Current Liabilities (Q) | 13.30M | |||
| Total Debt (Q) | 4.64M | |||
| Total Liabilities (Q) | 17.07M | |||
| Total Common Equity (Q) | 121.20M | |||
| Cash Flow | ACRV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 50.72M | |||
| Cash from Financing (TTM) | -1.55M | |||
| Net Change in Cash (TTM) | 6.52M | |||
| Levered Free Cash Flow (TTM) | -22.33M | |||
| Cash from Operations (TTM) | -42.64M | |||
